Gastrointestinal adverse events · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes gastrointestinal adverse events compared with combination (paracetamol and opioid) analgesic (very low certainty).
1 finding from 1 review
Neurological adverse effects · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes neurological adverse events compared with combination (paracetamol and opioid) analgesic (very low certainty).
1 finding from 1 review
Early re‐injury (with 3 months) · people with acute soft tissue injury, such as ankle sprain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · people with acute soft tissue injury, such as ankle sprain
1 finding from 1 review
Little or no swelling on day 7 or later · people with acute soft tissue injury, such as ankle sprain
NSAID showed no clear difference in little or no swelling on day 7 or later compared with paracetamol (low certainty).
1 finding from 1 review
Return to function on day 7 or later (numbers returning to full function or returning to training) · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes return to function on day 7 or latere compared with paracetamol (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with acute soft tissue injury, such as ankle sprain
NSAID showed no clear difference in gastrointestinal adverse events compared with paracetamol (low certainty).
1 finding from 1 review
Neurological adverse effects · people with acute soft tissue injury, such as ankle sprain
NSAID showed no clear difference in neurological adverse events compared with paracetamol (low certainty).
1 finding from 1 review
Early re‐injury (with 3 months) · people with acute soft tissue injury, such as ankle sprain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in pain intensity · acute soft tissue injury
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in serum albumin · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Mid‐arm muscle circumference · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Lean mass · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Quality of life · people with CKD requiring dialysis
1 finding from 1 review